Sai Parenterals Limited — Investor Meet, 29-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sai Parenterals Limited held an earnings conference call to discuss financial results and business outlook. Management highlighted the successful IPO and the acquisition of Noumed Pharmaceuticals as key milestones, transforming the company into a global IP-led platform. Strategic priorities include deepening integration of Noumed, expanding the CDMO export business, and developing its branded formulation segment. The company is investing in capacity expansion and R&D, with a target of INR750 crore revenue and 17% EBITDA margin for FY27, expecting full impact from investments in FY28. Investor sentiment appears positive, with management projecting growth and margin expansion through vertical integration and IP monetization.